Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 10;11(6):956.
doi: 10.3390/cells11060956.

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer

Michał Szczyrek  1 , Radosław Mlak  2 , Aneta Szudy-Szczyrek  3 , Kamila Wojas-Krawczyk  1 , Karolina Kędziora  4 , Janusz Milanowski  1
Affiliations

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer

Michał Szczyrek et al. Cells. .

Abstract

Non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancers. Currently, NSCLC therapy is based on the analysis of specific predictors, whose presence qualifies patients for appropriate treatment. Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), also known as "survivin", is a protein whose expression is characteristic for most malignant tumors and fetal tissue, while absent in mature cells. The biological role of BIRC5 is to counteract apoptosis by inhibiting the initiating and effector activities of caspases and binding to microtubules of the mitotic spindle. In our study, we looked for a relationship between BIRC5 gene polymorphism and the effectiveness of platinum-based chemotherapy. The study group consisted of 104 patients with newly diagnosed locally advanced or metastatic NSCLC. DNA was isolated from pretreatment blood samples, and SNPs of BIRC5 gene were analyzed. All patients received first-line platinum-based chemotherapy. Univariate analysis showed that a specific BIRC5 genotype was significantly associated with a higher risk of early progression (homozygous GG vs. heterozygous CG or CC: 28.9% vs. 11.9%). The presence of a homozygous GG genotype of the BIRC5 gene was insignificantly related to PFS shortening and TTP shortening. Moreover, significantly higher risk of overall survival shortening was associated with the BIRC5 homozygous GG genotype. Thus, studies on polymorphisms of selected genes affecting apoptosis may have a practical benefit for clinicians who monitor and treat NSCLC.

Keywords: BIRC5; NSCLC; Survivin; outcome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interest regarding the publication of this paper.

Figures

Figure 1
Figure 1
Kaplan–Meier curves representing probability of PFS shortening depending on BIRC5 genotype.
Figure 2
Figure 2
Kaplan–Meier curves representing probability of TTP shortening depending on BIRC5 genotype.
Figure 3
Figure 3
Kaplan–Meier curves representing probability of OS shortening depending on BIRC5 genotype.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014;64:9–29. doi: 10.3322/caac.21208. - DOI - PubMed
    1. American Cancer Society (2014) NSCLC: 5-Year Survival Rates. [(accessed on 1 October 2019)]. Available online: https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/su....
    1. Schrank Z., Chhabra G., Lin L., Iderzorig T., Osude C., Khan N., Kuckovic A., Singh S., Rachel J.M., Puri N. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. Cancers. 2018;10:224. doi: 10.3390/cancers10070224. - DOI - PMC - PubMed
    1. Lim S.M., Hong M.H., Kim H.R. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Netw. 2020;20:e10. doi: 10.4110/in.2020.20.e10. - DOI - PMC - PubMed
    1. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997;3:917–921. doi: 10.1038/nm0897-917. - DOI - PubMed

MeSH terms